Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-16, Stock:NVS, The news for the past five days is as follows:
2018-11-09: NEWS1: Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View.NEWS2: Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View.NEWS3: Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View.NEWS4: Novartis division Sandoz recalls one lot of blood pressure drug.
2018-11-12: NEWS1: These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece.
2018-11-13: NEWS1: Alcon Files Initial Registration Statement With SEC For Proposed Spin-off.NEWS2: Alcon Files Initial Registration Statement With SEC For Proposed Spin-off.NEWS3: Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?.NEWS4: Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe.NEWS5: Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe.NEWS6: Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?.NEWS7: Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?.NEWS8: Tilray (TLRY) to Report Q3 Earnings: What&apos;s in the Cards?.
2018-11-14: NEWS1: Migraine-Focused Biotech Has A Headache On Quarterly Losses.NEWS2: Can These 2 Battered Biotech Stocks Recover?.NEWS3: Can These 2 Battered Biotech Stocks Recover?.NEWS4: Roche's Tecentriq Gets Priority Review for Breast Cancer.NEWS5: Roche's Tecentriq Gets Priority Review for Breast Cancer.NEWS6: Novartis AG (NVS) Not Doing Enough to Attract Smart Money.
2018-11-15: NEWS1: Novartis launches third-to-market Remicade copy in Germany.NEWS2: The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere.NEWS3: The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere.NEWS4: The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere.NEWS5: Novartis 'completely committed' to Sandoz, has no split-off plan.NEWS6: Novartis 'completely committed' to Sandoz, has no split-off plan.NEWS7: Novartis says 'completely committed' to Sandoz, not planning split-off.

Answer: Rise